2H-咪唑-2-硫酮,1,3-二氢-1-[2-(苯基硫代)乙基]- | 104489-51-2

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: 2H-咪唑-2-硫酮,1,3-二氢-1-[2-(苯基硫代)乙基]-
• 英文名称: 1-(2-Phenylsulfanyl-ethyl)-1,3-dihydro-imidazole-2-thione
• 英文别名: 3-(2-phenylsulfanylethyl)-1H-imidazole-2-thione
• CAS: 104489-51-2
• 化学式: C₁₁H₁₂N₂S₂
• 分子量: 236.362
• InChiKey: PBQTYHGFBFHZRH-UHFFFAOYSA-N

物化性质

• 沸点：
  367.4±44.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  72.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  苯硫基乙酸 在 吡啶 、 盐酸 、 lithium aluminium tetrahydride 、 草酰氯 作用下， 以 四氢呋喃 、 乙醚 、 乙醇 、 二氯甲烷 为溶剂， 反应 11.0h， 生成 2H-咪唑-2-硫酮,1,3-二氢-1-[2-(苯基硫代)乙基]-
  参考文献：
  名称：

  Multisubstrate inhibitors of dopamine .beta.-hydroxylase. 1. Some 1-phenyl and 1-phenyl-bridged derivatives of imidazole-2-thione

  摘要：

  The synthesis and characterization of some 1-(phenylalkyl)imidazole-2-thiones as a novel class of "multisubstrate" inhibitors of dopamine beta-hydroxylase (DBH) are described. These inhibitors incorporate structural features that resemble both tyramine and oxygen substrates, and as evidenced by steady-state kinetics, they appear to bind both the phenethylamine binding site and the active site copper atom(s) in DBH. A series of structural congeners that incorporate different bridging chain lengths between the phenyl ring (dopamine mimic) and the imidazole-2-thione group (oxygen mimic) define the optimum distance for inhibitory potency and the likely intersite distance in the DBH active site. Additional bridging analogues were prepared to determine the active site bulk tolerance and the effects of heteroatom replacement.

  DOI：

  10.1021/jm00162a008

文献信息

• [EN] SELECTIVE NEUROPEPTIDE Y2 RECEPTOR AGONISTS<br/>[FR] AGONISTES RECEPTEUR Y2 NEUROPEPTIDIQUES SELECTIFS
  申请人：BAYER PHARMACEUTICALS CORP

  公开号：WO2006049681A2

  公开（公告）日：2006-05-11

  [EN] This invention provides peptides that act as selective NPY2 receptor agonists and may be used to reduce food intake. The invention includes a peptide selected from a specific group of derivatized NPY-related peptides, or functional equivalents thereof. The invention is also directed to a method of treating obesity or related diseases in a mammal comprising administering a therapeutically effective amount of the peptide to said mammal to reduce food intake and body weight.
  [FR] Cette invention concerne des peptides qui agissent en tant qu'agonistes récepteur NPY2 sélectifs et qui peuvent être utilisés afin de réduire l'ingestion d'aliments. L'invention concerne un peptide sélectionné dans un groupe spécifique de peptide associé à NPY dérivatisé, ou des équivalents fonctionnels de ceux-ci. L'invention concerne également un procédé de traitement de l'obésité ou de maladies associées chez un mammifère qui consiste à administrer une quantité efficace sur le plan thérapeutique du peptide au mammifère afin de réduire son ingestion d'aliments et son poids corporel.
• Multisubstrate inhibitors of dopamine .beta.-hydroxylase. 1. Some 1-phenyl and 1-phenyl-bridged derivatives of imidazole-2-thione
  作者：Lawrence I. Kruse、Carl Kaiser、Walter E. DeWolf、James S. Frazee、Eleanor Garvey、Eileen L. Hilbert、Wayne A. Faulkner、Kathryn E. Flaim、John L. Sawyer、Barry A. Berkowitz

  DOI：10.1021/jm00162a008

  日期：1986.12

  The synthesis and characterization of some 1-(phenylalkyl)imidazole-2-thiones as a novel class of "multisubstrate" inhibitors of dopamine beta-hydroxylase (DBH) are described. These inhibitors incorporate structural features that resemble both tyramine and oxygen substrates, and as evidenced by steady-state kinetics, they appear to bind both the phenethylamine binding site and the active site copper atom(s) in DBH. A series of structural congeners that incorporate different bridging chain lengths between the phenyl ring (dopamine mimic) and the imidazole-2-thione group (oxygen mimic) define the optimum distance for inhibitory potency and the likely intersite distance in the DBH active site. Additional bridging analogues were prepared to determine the active site bulk tolerance and the effects of heteroatom replacement.